Calycosin

Calycosin is an isoflavone compound primarily found in Astragalus membranaceus that exhibits immunomodulatory properties through T cell regulation. Research indicates it may support immune function by suppressing pathogenic T follicular helper cells and reducing autoantibody production.

Origin & History

Calycosin is a bioactive isoflavone extracted from Astragalus membranaceus (astragalus root), a plant widely used in traditional Chinese medicine for over 2,000 years. It is typically isolated through solvent extraction methods from the plant's root material and functions as a phytoestrogen that can interact with estrogen receptors in the body.

Historical & Cultural Context

Calycosin is derived from Astragalus membranaceus, a cornerstone herb in Traditional Chinese Medicine used for over 2,000 years to strengthen immune function, support energy (qi), and promote wound healing. While the plant has extensive traditional use, specific historical documentation of calycosin as an isolated compound predates modern extraction techniques.

Health Benefits

• May support immune function by suppressing pathogenic T follicular helper cells and reducing autoantibody production (preliminary evidence from cell studies and one human validation study, PMID: 40181166)
• Potential neuroprotective effects against Parkinson's disease by inhibiting TLR/NF-κB and MAPK pathways (animal studies only)
• May help maintain healthy skin barrier function by reducing inflammatory cytokines and restoring tight junction proteins (preclinical evidence)
• Shows anti-cancer properties in multiple cell line studies including pancreatic, colorectal, and lung cancers (in vitro evidence only)
• Demonstrates antioxidant activity through activation of the Nrf2 pathway (cell culture studies)

How It Works

Calycosin modulates immune function by suppressing pathogenic T follicular helper cells and reducing autoantibody production through unknown molecular pathways. It demonstrates neuroprotective effects by inhibiting TLR/NF-κB signaling cascades, which reduces inflammatory responses in neural tissue. The compound's isoflavone structure allows it to interact with various cellular receptors and inflammatory mediators.

Scientific Research

Current clinical evidence for calycosin is limited primarily to preclinical studies, with only one study validating immunomodulatory findings in human peripheral blood mononuclear cells from patients with Sjögren's disease (PMID: 40181166). A 2025 review (PMID: 33346681) explicitly noted that clinical research trials are needed to establish suitable medicinal concentrations for different diseases and validate findings in human subjects.

Clinical Summary

Evidence for calycosin primarily comes from cell culture studies and limited human research. One human validation study (PMID: 40181166) demonstrated immune-modulating effects through T follicular helper cell suppression, though sample size and study duration are not specified in available data. Most research remains in preliminary stages with cell-based studies showing neuroprotective potential against Parkinson's disease. Additional human clinical trials are needed to establish therapeutic dosages and confirm efficacy in larger populations.

Nutritional Profile

Calycosin is a pure bioactive isoflavonoid compound (molecular formula: C16H12O5, molecular weight: 284.27 g/mol), not a whole food ingredient, therefore it contains no macronutrients (zero protein, fat, carbohydrate, or fiber), no vitamins, and no minerals in its isolated form. It is a 3'-hydroxy-formononetin, classified as a phytoestrogenic isoflavone predominantly extracted from Astragalus membranaceus (Huangqi) root, where it occurs at concentrations of approximately 0.01–0.05% dry weight of the raw herb. As a pure compound, its 'nutritional profile' is defined entirely by its bioactive properties: it exhibits selective estrogen receptor modulator (SERM)-like activity with binding affinity for ERβ over ERα. Bioavailability data from animal studies suggests moderate oral absorption with hepatic first-pass metabolism converting it to glucuronide and sulfate conjugates; peak plasma concentrations (Cmax) in rodent models range approximately 50–200 ng/mL following doses of 20–50 mg/kg. In standardized Astragalus extracts, calycosin-7-O-β-D-glucoside (the glycoside form) is more abundant than the aglycone and requires intestinal hydrolysis for activation. Lipophilicity (logP ≈ 2.1) suggests moderate membrane permeability. No dietary reference intake or recommended daily allowance exists for this compound.

Preparation & Dosage

Preclinical dosage ranges studied in animal models include 25-50 mg/kg for cancer models and 0-100 μM for in vitro studies. No established clinically validated dosage for human use has been determined, and standardized extract formulations with defined calycosin concentrations are not well-characterized in the literature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Methotrexate (for autoimmune conditions), Astragalus whole extract, Antioxidant compounds, Nrf2 activators

Safety & Interactions

Safety data for calycosin supplementation in humans is limited due to minimal clinical research. As an isoflavone compound, it may interact with hormone-sensitive conditions or medications affecting estrogen metabolism. Potential interactions with immunosuppressive drugs should be considered given its T cell modulating effects. Pregnant and nursing women should avoid calycosin supplements due to insufficient safety data and potential hormonal activity.